Through sequencing analysis of blood or bone marrow samples from patients with chronic myeloid leukemia, we identified BCR-ABL kinase domain mutations in 29 of 32 patients whose disease relapsed after an initial response to the tyrosine kinase inhibitor imatinib. Fifteen different amino acid substitutions affecting 13 residues in the kinase domain were found. Mutations fell into two groups-those that alter amino acids that directly contact imatinib and those postulated to prevent BCR-ABL from achieving the inactive conformational state required for imatinib binding. Distinct mutations conferred varying degrees of imatinib resistance. Mutations detected in a subset of patients with stable chronic phase disease correlated with subsequent disease progression. Multiple independent mutant clones were detected in a subset of relapsed cases. Our data support a clonal selection model of preexisting BCR-ABL mutations that confer imatinib resistance.
Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia Introduction CML achieve hematologic responses to imatinib, and the Ph chromosome is no longer detected in about 50% of these paThe tyrosine kinase BCR-ABL is the fusion product of a reciprotients using standard cytogenetic assays (termed cytogenetic cal chromosome translocation between chromosomes 9 and response) (Druker et al., 2001b; Kantarjian et al., 2002) . Approxi-22, known as the Philadelphia (Ph) chromosome, and is present mately 60% of patients with advanced-stage CML (blast crisis) in the leukemic cells of more than 95% of patients with chronic respond to imatinib, but nearly all these patients relapse despite myeloid leukemia (CML) (Sawyers, 1999) . The ability of BCRcontinued therapy (Druker et al., 2001a; Sawyers et al., 2002) . ABL to produce a CML-like disease in mouse models (Daley et We previously demonstrated that BCR-ABL kinase activity is inhibited in leukemic cells at the time of response but is reactial., 1990; Elefanty et al., 1990; Kelliher et al., 1990) led to efforts to develop inhibitors of its kinase activity. Imatinib (STI571, vated at relapse (Gorre et al., 2001a) . This result suggested that BCR-ABL maintains a crucial role throughout disease progresGleevec) was approved for CML treatment after striking efficacy was demonstrated in all stages of the disease (Druker et al., sion in CML. Detailed analysis of 11 such patients revealed at least two distinct mechanisms for resistance-BCR-ABL gene Kantarjian et al., 2002; Sawyers et al., 2002; Talpaz et al., 2002) . The clinical success of this small molecule amplification or point mutations in the kinase domain that presumably interfere with drug-protein binding without compromiskinase inhibitor has led to the notion that other selective tyrosine kinase inhibitors may have significant activity against a range ing kinase activity (Gorre et al., 2001a) . While these findings have been confirmed in additional small studies (Branford et of human malignancies.
Ninety percent of patients with early-stage (chronic phase) al. , 2002; Hofmann et al., 2002; von Bubnoff et al., 2002) , there is
S I G N I F I C A N C E
Chronic myelogenous leukemia represents the first human malignancy to be successfully treated with a small molecule tyrosine kinase inhibitor. Clinical resistance to this inhibitor (imatinib) has been reported in small numbers of patients due to BCR-ABL gene mutation or amplification. Here we present a comprehensive analysis of CML patients in varying stages of disease that documents a very high frequency of BCR-ABL kinase domain mutations in patients that develop imatinib resistance. These results reinforce the central importance of BCR-ABL in the pathogenesis of this disease, even at the most advanced stages, and define the challenges necessary to design second generation targeted therapies. Our findings may also have implications for other kinase inhibitors currently in development against a broad range of cancers. While the focus is on content and clarity, a scientific article should read as a narrative in the sense that the transitions (including headings & titles) guide the reader through the different sections and present why the various steps were taken.
The Introduction of an Honors Thesis will include more background and details that explain why the experiment is taking place to make the context and significance clear."Significance" is usually not separated into its own section, however the scope of the article can be addressed within the intro or on its own. disagreement about the frequency with which mutations occur specificity of our methodology, a mutation was deemed present if it was detected on both strands of DNA in two independent (Barthe et al., 2001; Hochhaus et al., 2001 ). In addition, other mechanisms of imatinib resistance have been proposed, such isolates from the same patient (therefore representing approximately 20% of the total population of BCR-ABL mRNA tranas drug sequestration mediated by the serum protein ␣-1 acid glycoprotein (AGP) (Gambacorti-Passerini et al., 2000) , or drug scripts). Samples from 32 CML patients who relapsed after a hematoefflux by multidrug resistance pumps (Mahon et al., 2000) . To date, neither of the latter mechanisms has been implicated in logic response to imatinib were analyzed (16 with myeloid blast crisis, 5 with lymphoid blast crisis, and 11 with chronic phase). patients (Jorgensen et al., 2002) .
Clinical efforts to overcome imatinib resistance must begin Mutations were identified at the time of relapse in 29 of the 32 patients (15 of 16 with myeloid blast crisis, 4 of 5 with lymphoid by defining the most common mechanisms of resistance in a larger number of patients. As a first step, we conducted compreblast crisis, and 10 of 11 with chronic phase) ( Table 1) . Mutations mapped to 13 different amino acid residues in the ABL kinase hensive BCR-ABL kinase domain sequencing analysis of 45 CML patients who demonstrated imatinib resistance. Mutations domain and predicted 15 different codon changes (Figure 1 ). Nucleotide changes affecting two residues, Q252 and Y253, were detected in over 90% of patients (29 of 32) who relapsed after an initial response to imatinib, including those with chronic led to two alternative amino acid substitutions each-Q252H/R and Y253F/H. Mutations in seven of these residues have been phase, myeloid blast crisis, and lymphoid blast crisis CML. Mutations led to 15 amino acid substitutions in 13 different residues reported in smaller studies (Branford et al., 2002; Gorre et al., 2001a; Hofmann et al., 2002; von Bubnoff et al., 2002) ; six which, based on known crystal structure data, include direct drug contact sites as well as sites that presumably impair the mutations detected are novel. Mutations were detected at each of the variable (X) amino acids of the kinase consensus sequence conformational change in the kinase domain required to accommodate imatinib binding. Mutant BCR-ABL alleles retain bioGly-X-Gly-X-X-Gly-X-Val located in the P loop, which provides a number of important contacts for ATP binding. One of these logic activity but show varying degrees of resistance to imatinib in biochemical and biological assays. Mutations were also demutations, E255K, in addition to mutations T315I and M351T, accounted for over 60% of the cases. To address whether the tected in 4 of 13 chronic phase patients with stable disease and correlated with subsequent clinical relapse. Additional obhigh frequency and variety of kinase domain mutations represented artifact introduced during the PCR amplification process, servations that multiple independent imatinib-resistant clones were detected in some patients (polyclonal resistance) and that we sequenced ten independent subclones of the ABL kinase domain obtained from each of two healthy blood donors. Using kinase domain mutations were detected prior to treatment in some patients with imatinib-refractory myeloid blast crisis proour criteria of at least two independent isolates out of ten clones, we found no evidence of ABL kinase domain mutation. We vide evidence that mutations develop as a consequence of clonal selection rather than generalized hypermutability. Collectherefore conclude that the BCR-ABL kinase domain mutations described here are unlikely to be the result of PCR-introduced tively these results establish the primary role of BCR-ABL kinase domain mutations as a cause of imatinib resistance in CML error.
To gain insight into potential mechanisms by which these and provide evidence that knowledge of mutation status might influence clinical management. The spectrum of mutations idenmutations might confer imatinib resistance, we modeled each amino acid substitution onto the known cocrystal structure of tified provides new insights into kinase domain function and into novel treatment strategies to overcome resistance.
the ABL kinase domain bound to imatinib ( Figure 2A ; Nagar et al., 2002; Schindler et al., 2000) . The mutations fall into two groups. The first group includes mutations at sites that directly Results contact imatinib (T315, F317, and F359) and presumably impair drug binding without significantly affecting the binding of ATP Kinase domain mutations are detected in 90% of CML patients who relapse after responding to imatinib ( Figure 2A , red spheres). The second group includes mutations in residues located in distinct regions, all of which are implicated The ability to detect BCR-ABL mutations in imatinib-resistant CML cells is dependent on patient selection and the sensitivity in the unique conformational change that the kinase domain must undergo to accommodate imatinib. For example, the ATP of the assay used. Because the Ph chromosome translocation occurs in a pluripotent hematopoietic stem cell, nearly all the phosphate binding loop (P loop) is distorted in the imatinib/ABL structure such that it forms a hydrophobic cage for the drug. blood and bone marrow cells in untreated CML patients express the BCR-ABL fusion gene. In patients with a hematologic response Resistance mutations observed in the P loop region (G250, Q252, Y253, and E255) are likely to destabilize the distorted to imatinib (normalization of blood counts) and a cytogenetic response (reduction in the fraction of Ph chromosome-conshape ( Figure 2A , green spheres). Y253 inserts into the ATP binding site, forming one wall of a hydrophobic pocket for the taining cells), a significant fraction of the BCR-ABL-expressing cells isolated at the time of relapse will represent the drugdrug, and is stabilized by hydrogen bonds formed by the hydroxyl group of the side chain ( Figure 2B ). Y253H/F substitutions resistant clone. However, in patients who relapse on imatinib after a hematologic response but no cytogenetic response, imawould break the hydrogen bonding interactions of the tyrosine side chain, which is also specific for the distorted conformation tinib-resistant cells represent only a subset of the total BCR-ABL-expressing cells (often 20% or less) (Gorre et al., 2001b) .
of the P loop. E255 forms hydrogen bonds that bridge the side chains of K247 and Y257, an interaction that appears to be To optimize the sensitivity of mutation detection, we performed RT-PCR amplification of BCR-ABL mRNA from CML patient specific to the distorted conformation of the P loop. Mutation of E255 presumably destabilizes the P loop conformation that blood or bone marrow cells, subcloned the PCR products (rather than sequence the products directly), and sequenced ten indeis required for imatinib binding. A second structural change required for imatinib binding is pendent PCR products per patient sample. To improve the Duration of imatinib therapy at the time of analysis is shown. The fraction of independent clones for each mutation is given. Patients 2, 6, 8, 18, and 20 had major cytogenetic responses and patients 17 and 29 had minor cytogenetic responses prior to relapse, using criteria previously described (Kantarjian et al., 2002) . Patients 10, 13, and 31 had evidence of BCR-ABL gene amplification at relapse by FISH analysis. Patient 37 (NCR) harbors a kinase domain mutation but has not suffered progressive disease (see also Figure 4 ). Eight additional NCR patients, as depicted in Figure 4 , had no evidence of kinase domain mutation, and are not represented here. Abbreviations: MBC, relapsed myeloid blast crisis; LBC, relapsed lymphoid blast crisis; CP, relapsed chronic phase; P-MBC, preimatinib sample from myeloid blast crisis patients whose disease was subsequently refractory; and NCR, chronic phase with hematologic response but no cytogenetic response. the closed conformation of the ABL activation loop, which is getic balance required to stabilize the closed conformation of the activation loop ( Figure 2C ). Another cluster of mutations part of a network of interactions that help stabilize the drug binding site. In the closed conformation, Y393 in the activation involves amino acids located in the C-terminal lobe of the kinase (E355, M351, and V379) in a region that provides a platform for loop is positioned such that it mimics the tyrosine residue of a peptide substrate. The H396R substitution is located close to the base of the activation loop. While it is difficult to predict the precise energetic consequences of mutations at these residues, Y393, such that mutations in this region might disturb the ener- (Nagar et al., 2002) , depicting resistant mutations. Imatinib is shown in gold. Positions 1-3 (red) are mutations that directly affect imatinib binding. All other positions are those that likely affect the ability of the kinase to achieve the conformation required to bind imatinib, including those in the P loop (4-8; green) and those in the vicinity of the activation loop (9-13; cyan). The activation loop is colored purple. The positions of amino acids found mutated are depicted by spheres: 1, F317; 2, T315; 3, F359; 4, M244; 5, G250; 6, Q252; 7, Y253; 8, E255; 9, M351; 10, E355; 11, V379; 12, L387; 13, H396. B: Comparison of the P loop in the ABL:imatinib structure (left) with that of active insulin receptor kinase (IRK) (right) (Hubbard, 1997) . Glu 255 in the P loop (green) of ABL makes strong interactions with Tyr 257 and Lys 247. The P loop is distorted, with Tyr 253 swung into the ATP binding site, forming a hydrophobic face against which imatinib packs. In IRK, the P loop (blue) is folded out over the nucleotide. Orange spheres indicate Mg 2ϩ ions associated with nucleotide. Representation constructed using a previously described program (Evans, 1993) . C: Mutations located at sites that could influence conformational changes undergone by the activation loop. For comparison, the activation loop of Lck (an active tyrosine kinase) is shown in gold, including the phosphorylated Tyr residue (pTyr 394) (Yamaguchi and Hendrickson, 1996) . Tyr 393, the site of activating phosphorylation in ABL, is shown in blue. Positions of mutations M351T, E355G, V379I, L387M, and H396R are depicted as spheres (cyan).
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CANCER CELL : AUGUST 2002 all three are located adjacent to a region where large torsional hematologic relapse, we asked if similar mutations might be found in cytogenetic nonresponders with sustained hematologic rotations are required to accommodate imatinib. Comparative crystallographic studies of mutant ABL alleles are required to remissions. Four of 13 such chronic phase patients had mutations. Three of these mutations (E255K, F317L, and F359V) are precisely define the structural consequences of these mutations.
identical to those observed in cases of relapsed myeloid blast crisis described above, whereas the fourth mutation (V379I) has not been previously documented. We next asked if detection Mutant BCR-ABL alleles show varying degree of imatinib resistance in vitro of a mutation during this time of stable hematologic response correlated with clinical outcome. Three of the four patients with To address the causal role of these mutations in imatinib resistance, we generated mutant alleles by site-directed mutagenekinase domain mutations suffered disease progression within 18 months of mutation detection, whereas only one of nine sis of wild-type BCR-ABL and expressed the mutants in the interleukin-3 (IL-3)-dependent cell line Ba/F3. BCR-ABL activity patients without a detectable mutation progressed (Figure 4) . Of note, the patient without evidence for a kinase domain mutahas been shown to render Ba/F3 cells IL-3 independent (Daley and Baltimore, 1988) . The T315I and E255K mutations are tion had BCR-ABL gene amplification at relapse based on fluorescence in situ hybridization analysis (data not shown). The known to confer IL-3 independence as well as biochemical and biological resistance to imatinib in this system (Gorre et al., patient harboring the novel V379I mutation continues to have a complete hematologic remission but no cytogenetic response , 2002 von Bubnoff et al., 2002) and were included as controls. Six previously uncharacterized mutants were chosen at 18 months. Although the number of patients is small, these findings suggest that periodic assessment of the mutational for this initial analysis based on their frequency of isolation and location within the kinase domain. IL-3-independent Ba/F3 status of the BCR-ABL kinase domain may have prognostic utility. populations were derived for all six mutants studied, demonstrating that each of these mutants retains biologic activity comparable to wild-type BCR-ABL in this system. The effect of imatinib Evidence for clonal selection of preexisting BCR-ABL kinase domain mutations concentrations ranging from 0.5 to 10 M on BCR-ABL kinase activity and cellular viability was determined using standard
The most frequent explanation for single-nucleotide substitutions in the human genome are methylation-deamination reacassays ( Figure 3 ). As expected, the T315I and E255K mutants were highly resistant to imatinib with IC 50 values greater than tions that give rise to C/T or G/A transitions in the context of the CpG dinucleotide sequence. This mechanism is estimated 10-fold higher than wild-type BCR-ABL (Table 2) . G250E-expressing cells were also markedly resistant. Y253F also reto account for about 25% of all reported nucleotide changes based on comprehensive analysis of human genetic disorders sulted in considerable resistance, but clearly less than T315I, consistent with another report that characterizes the effects of (Vogelstein and Kinzler, 1997). Remarkably, only 1 of the 15 mutations we observed (E255K) could be explained on that this same mutation on ABL kinase function (Roumiantsev et al., 2002) . Four mutations (Q252H, F317L, M351T, and E355G) basis. Alternatively, the high frequency of kinase domain mutations observed in our study could reflect a global increase in conferred only moderate resistance to imatinib, retaining biochemical sensitivity at drug concentrations of 1-4 M. Since mutation frequency (hypermutation) as a consequence of genetic instability. To address this possibility, we looked for mutadrug levels approaching this concentration can be clinically achieved in some patients, these results raise the possibility tions in other regions of the genome by sequencing a 700 bp region of BCR-ABL immediately 5Ј to the kinase domain in five that resistance caused by certain mutations might respond to high-dose imatinib treatment. The fact that all BCR-ABL mupatients in whom kinase domain mutations were detected in a large fraction of the original clones sequenced. No evidence tants tested show imatinib resistance in vitro provides strong evidence that each of these mutations plays a causal role in of additional mutation was found in these samples. We also assessed the kinase domain of the related tyrosine kinase KIT, clinical imatinib resistance. Biochemical characterization of the five remaining mutations found, consisting of the novel mutawhich resides on chromosome 4 and exhibits sensitivity to imatinib at concentrations equivalent to BCR-ABL, in the same tions M244V, F359V, V379I, and L387M, in addition to the previously described H396R, will require additional studies.
group of five patients. No evidence of KIT kinase domain mutation was detected, arguing against a model of widespread genomic instability.
Potential predictive value of mutation detection in patients with stable disease
Another possible explanation for the high frequency of mutations is that exposure to imatinib might induce genetic instability, The overwhelming majority of CML patients on imatinib therapy have chronic phase disease. Although 90% of patients with particularly since the wild-type ABL kinase (which is also inhibited by imatinib) has been implicated in DNA repair (Kharbanda chronic phase CML achieve excellent hematologic control of their disease with imatinib, about half of these patients continue et al. , 1997; Shafman et al., 1997; Yoshida et al., 2002) . Several lines of evidence argue against this hypothesis. First, patients to have a significant number of Ph chromosome-containing cells in the bone marrow ("cytogenetic nonresponders"). Recent data with blast crisis CML often relapse within 1-3 months of initiating imatinib therapy, providing a short window of time for the acquisuggests that these patients progress to blast crisis more quickly that those who obtain cytogenetic remissions (Kantarjian sition of mutations and expansion of a drug-resistant clone. Second, we found multiple independent BCR-ABL mutations et al., 2002). The reason for failure to achieve a cytogenetic response is unknown, but may involve incomplete inhibition of (2-4 clones per patient) in 12 of the 32 patients with imatinib resistance, including 5 patients who relapsed within 3 months BCR-ABL kinase activity in progenitor cells or activation of BCR-ABL-independent survival pathways. Since BCR-ABL kinase of starting therapy (Table 1) . Unless we postulate an extremely high mutation rate, these results are most consistent with a domain mutations are prevalent in imatinib-treated patients with
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The transitions present why these steps were taken before specifying the results
Figure 3. BCR-ABL kinase domain mutants exhibit varying degrees of biochemical and biological resistance to imatinib
A: Western blot analysis using an anti-phosphotyrosine antibody (4G10) or anti-ABL antibody of lysates prepared from IL-3-independent Ba/F3 populations infected with retroviruses expressing the BCR-ABL isoforms indicated. Cells were exposed to the concentrations of imatinib indicated for 2 hr. B: Ba/F3 populations stably expressing mutant BCR-ABL isoforms were plated in the presence of varying concentrations of imatinib in triplicate, and viable cell counts were performed after 48 hr of exposure. Cell counts were normalized to the number of viable cells from control cultures grown in the absence of imatinib.
model whereby mutant clones preexist in some patients at levels mutation, when engineered into ABL, has demonstrated oncogenic activity (Allen and Wiedemann, 1996) . The mechanism for below our threshold for detection, then expand under the selective pressure of imatinib treatment. Definitive evidence for this the underlying increase in genetic instability that presumably leads to these mutations in CML cells remains to be defined. hypothesis was obtained by analysis of pretreatment samples from four blast crisis patients who failed to achieve even a transient response to imatinib (primary or de novo hematologic Discussion resistance). One patient exhibited T315I prior to initiation of therapy, as well as a separate BCR-ABL clone that contained
In a comprehensive analysis of CML patients treated with imatinib in all phases of the disease, we find that mutations in the two mutations, M343T and F382L, on the same DNA sequence. A second patient had the E255K mutation (Table 1) . Collectively, BCR-ABL kinase domain occur in over 90% of patients who relapse after an initial response. The high frequency of mutation these data indicate that BCR-ABL kinase domain mutations can occur during the natural evolution of CML and that those capadetection in our study relative to smaller studies reported by other investigators is most likely explained by differences in ble of conferring imatinib resistance expand under the selective pressure of imatinib treatment. The fact that certain mutations assay sensitivity. By subcloning and sequencing ten independent clones from each patient, we can reliably and confidently can be detected in a significant fraction of cells prior to imatinib therapy suggest that some mutations may confer gain of funcdetect mutant clones representing approximately 20% of the total population of BCR-ABL-expressing cells. This strategy also tion, analogous to a kinase domain mutation present in v-Abl, which has been shown to contribute to its oncogenic potential allows detection of polyclonal resistance, which would be extremely difficult to find using direct sequencing methods (with-(Jackson et al., 1993) . Members of the Src family of kinases, which have increased kinase activity relative to ABL, all have a out subcloning) because the mixture of wild-type and mutant clones would most likely be read as consensus wild-type sephenylalanine at amino acid position 5 in the P loop, whereas ABL has a tyrosine at this position. Furthermore, the Y253F quence. A second issue likely to explain differences in mutation
The first paragraph summarizes the overall "Discussion" frequency is patient selection, particularly if analysis is perresistance do so by preventing the kinase domain from achieving the closed conformation necessary for imatinib binding (as formed on patients who fail to have a hematologic response to imatinib. Having defined a large number of amino acid substituproposed in Figure 2 ), one can envision that inhibitors that bind ABL in the open configuration might retain activity against many tions, we obtained definitive evidence from in vitro reconstitution studies that at least eight mutants (all those studied to date) of these mutants. Indeed, we have evidence that the E255K mutant remains sensitive to such a dual ABL/SRC inhibitor (M. play a causal role in imatinib resistance. The role of the remaining seven (less common) mutations will need to be examined using Moasser, N. Rosen, M.E.G., and C.L.S., unpublished data). Alternatively, it may be necessary to inhibit BCR-ABL signaling similar assays before definitive conclusions about these mutants can be made. Our results reinforce the central role of BCR-ABL using completely different strategies that do not require binding to the kinase domain. Possibilities include the induction of BCRkinase activity in CML at all disease stages and clearly delineate the challenge that future targeted therapeutic strategies for CML ABL protein degradation using inhibitors of the molecular chaperone Hsp90 or blockade of critical signal transduction events must address.
Are there any obvious strategies that should be considered? that function downstream of BCR-ABL such as the RAF/MEK/ ERK and PI3K/AKT pathways. We have preclinical evidence in The complex array of different mutations observed in these patients makes it difficult to envision a single second generation support of the former strategy based on the fact that two Hsp90 inhibitors, geldanamycin and 17-AAG, have potent in vitro activ-ABL kinase inhibitor that would have activity against all mutants. However, recent insights gained from structural analysis of ABL ity against the T315I and E255K BCR-ABL mutants . bound to imatinib versus a dual ABL/SRC inhibitor indicate that two different inhibitors can bind to the same kinase in different As second generation inhibitors undergo development, it may be useful now to measure the mutation status of the BCRconformational states (Nagar et al., 2002; Schindler et al., 2000) . If a significant number of the mutations that cause imatinib ABL kinase domain in selected populations of CML patients Thirteen chronic phase patients treated at UCLA with imatinib who had sustained hematologic response in the absence of cytogenetic response were studied. Patients were categorized with respect to the presence of BCR-ABL kinase domain mutations at the time of analysis. Progression is defined as loss of previously achieved hematologic response to imatinib. The four patients who progressed were reevaluated for the presence of mutation at the time of progression. Data obtained at the time of progression is included in Table 1 ( patients 23-25, 31) . The one patient with a kinase domain mutation who did not have disease progression is also listed in Table  1 (patient 37). P value obtained by exact logrank test.
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The rest of the "Discussion" then details the more specific issues related to the experiment's long term limitations & significance
The kinase domain of c-KIT was amplified using the following primers:
treated with imatinib. Our analysis of a small number of chronic 5Ј-TGAGGAGATAAATGGAAACAA-3Ј and 5Ј-AACTCGTCATCCTCCATGAT-3Ј.
phase patients with stable hematologic control but no cytoge- require a less cumbersome method for mutation detection than 293T cells maintained in DMEM with 10% fetal calf serum were cotransthat described here, perhaps using mutation-specific assays.
fected by the calcium phosphate method with mutant P210 expression vectors and a packaging plasmid (Ecopack, kindly provided by R. van Etten).
The fact that only three mutations (T315I, E255K, and M351T) Media containing virus was filtered and used to infect Ba/F3 cells grown in account for more that 60% of the cases in our study provides RPMI supplemented with 10% fetal calf serum and IL-3. Stable lines were a starting point for the development of such clinical tests. factors that lead to the high frequency of mutations. By default, HEPES (pH 7.5), 150 mM NaCl, 1% Triton X-100, 10% glycerol, 1 g/ml we assume that CML cells have increased genomic instability, aprotinin, 100 g/ml PMSF, and 2 g/ml leupeptin. Seventy-five micrograms as is clearly evident in blast crisis where a range of secondary of total protein were analyzed by Western blot using anti-ABL antibody AB-3 chromosomal changes are frequently observed. The fact that concentrations was normalized to mean value of viable cells in the 0 mM imatinib sample. Biological IC 50 was determined from semilogarithmic graphAfter obtaining informed consent to participate in a research protocol aping of the 48 hr time point for each mutant. proved by the UCLA institutional review board, blood or bone marrow samples were obtained from patients enrolled in clinical trials assessing the Acknowledgments efficacy of imatinib in the treatment of CML. Criteria for determination of response and relapse were as defined in the phase I studies of imatinib in We thank Elliott Landaw for statistical analysis, Tom Graeber for bioinfor-CML (Druker et al., 2001a (Druker et al., , 2001b . RNA was extracted using TriReagent or matic assistance in sequence analysis, Liz Haddad and Nancy Violasse for TriAzol. CDNA synthesis was performed using MMLV reverse transcriptase.
assistance with clinical follow-up, Gary Shih for help with processing of Polymerase chain reaction (PCR) was performed using the following primers: samples, and Phuong Huynh for manuscript preparation. Additionally, we CM10 (5Ј-GAAGCTTCTCCCTGACATCCGT-3Ј) and 3Ј ABL KD (5Ј-GCCAG would like to thank Gordon Averbook for his generosity. This work was GCTCTCGGGTGCAGTCC-3Ј). The resultant 1.3 kb fragment was excised supported by grants from the Leukemia and Lymphoma Society (N.P.S. and from a low melting point agarose gel following electrophoresis. A second C.L.S.) and USPHS National Research Service Award GM07185 (M.E.G.). PCR was performed on the gel-purified 1.3 kb fragment to isolate the kinase C.L.S. is a Doris Duke Distinguished Clinical Scientist. This work is dedicated domain using the primers 5Ј ABL KD (5Ј-GCGCAACAAGCCCACTGTCTA to the memory of Francis R. Nicoll, Jr. TGG-3Ј) and 3Ј ABL KD. The resultant 0.6 kb fragment was subcloned into pBluescript II KSϩ digested with Eco RV. Bacterial transformants were plated on media containing ampicillin and X-gal. Ten white colonies per cDNA were inoculated into media and miniprep DNA was isolated. Sequencing of Received: July 16, 2002 each clone was performed using M13 universal forward and reverse primers.
Revised: July 23, 2002
Because two rounds of amplification were employed, a mutation was considered present if it was detected on both strands of at least two independent References clones per patient (see Figure 1) . Analysis of the ABL kinase domain from two healthy blood donors was performed using PCR of the ABL kinase domain, followed by subsequent reamplification to control for the number Allen, P.B., and Wiedemann, L.M. (1996) . An activating mutation in the ATP of amplification cycles to which patient samples were subjected. Sequence binding site of the ABL kinase domain. J. Biol. Chem. 271, 19585-19591 . analysis of a 0.7 kb portion of BCR-ABL immediately 5Ј to the kinase domain Barthe, C., Cony-Makhoul, P., Melo, J.V., and Mahon, J.R. (2001) . Roots of was performed by amplification of the previously described 1.3 kb fragment clinical resistance to STI-571 cancer therapy. Science 293, 2163. using CM10 and 5Ј ABL KD reverse complement (5Ј-CCATAGACAGTGG GCTTGTTGCGC-3Ј) followed by ligation into pBluescript II KSϩ as above.
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Also called "Methods"
In an honors thesis it would be appropriate to more clearly structure the "Methods" section with subcategories rather than only paragraphs of text
